Gates Foundation awards VitriVax $3.6M for polio-vaccine development

BOULDER — VitriVax Inc., a Boulder company that is developing vaccine technology, said this week that it was recently awarded a $3.6 million grant from the Bill & Melinda Gates Foundation to help “fund development of a polio vaccine formulation for possible inclusion in combination pediatric vaccines.”

This is the second time in as many years that VitriVax has been the recipient of Gates Foundation grant money. The company got $5 million last year to further develop its proprietary single shot, thermostabilization vaccine technology.

“Funding support from the Bill & Melinda Gates Foundation allows us to continue our efforts to advance global accessibility to human vaccines,” VitriVax CEO Romulo Colindres said in a prepared statement. “We are honored to be part of the global drive to protect children from polio infection and contribute to polio eradication efforts.”
By the end of the year, VitriVax, which is in the process of taking over a 40,000-square-foot facility in Boulder, expects to have more than 40 employees, a company representative told BizWest. The new facility represents a quadrupling of the company’s local footprint and VitriVax expects further expansion in 2025.

on Facebook on LinkedIn